[Featured Stock] Medipost Prepares for US Phase 3 of 'Cartistem'... Global Technology Export Efforts Increase

Medipost is showing strong performance. This is interpreted as being influenced by news that it is pursuing global technology export of its stem cell treatment for knee osteoarthritis, 'Cartistem.'

As of 2:13 PM on the 15th, Medipost is trading at 6,500 KRW, up 13.84% compared to the previous day.

Medipost participated in the latest American Regenerative Medicine Alliance (ARM) 'Cell & Gene Meeting on the Mesa' held in Arizona, USA, until the 9th. At this event, by invitation of the organizers, it presented achievements in clinical trials, gene editing, tissue engineering, and regenerative medicine technologies. It discussed business development through one-on-one meetings with numerous pharmaceutical and biotech companies.

At the event, Executive Director Seungjin Lee of Medipost shared the excellence of 'Cartistem' and the progress of global clinical trials. Since receiving domestic product approval in 2012, 'Cartistem' has been administered to more than 30,000 patients. Currently, Phase 3 clinical trials are underway in Japan, and preparations for Phase 3 are ongoing in the United States.

Medipost also attended BioJapan held in Yokohama, Japan, until the 11th, where it gave an oral presentation on the status of the Phase 3 trials in Japan. It subsequently discussed partnerships and technology exports with global pharmaceutical and biotech companies such as Novartis and Bayer.